Key Points
- Executive VP George Fennell sold 11,345 shares on Feb. 10 at an average price of $646.72 for proceeds of about $7.34 million, cutting his stake by 53.6% to 9,823 shares valued around $6.35 million.
- IDEXX beat quarterly expectations, reporting $3.08 EPS vs. $2.93 expected and $1.09 billion in revenue (up 14.3% year-over-year), and set FY2026 EPS guidance of $14.29–$14.80 while analysts maintain a "Moderate Buy" consensus with a $783.33 average price target.
IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) EVP George Fennell sold 11,345 shares of the company's stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares of the company's stock, valued at $6,352,730.56. This represents a 53.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
IDEXX Laboratories Price Performance
NASDAQ:IDXX opened at $648.73 on Thursday. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The business's 50-day simple moving average is $688.69 and its two-hundred day simple moving average is $666.93. The stock has a market cap of $51.80 billion, a PE ratio of 49.64, a P/E/G ratio of 3.93 and a beta of 1.67. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.15. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business's quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have recently commented on the stock. BTIG Research lowered their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a report on Tuesday, February 3rd. Barclays decreased their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a research note on Thursday, February 5th. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research report on Monday, November 3rd. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research report on Monday, November 3rd. Finally, Wall Street Zen upgraded IDEXX Laboratories from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 7th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $783.33.
Read Our Latest Stock Analysis on IDEXX Laboratories
Institutional Trading of IDEXX Laboratories
Several hedge funds and other institutional investors have recently bought and sold shares of IDXX. Virtus Advisers LLC acquired a new stake in IDEXX Laboratories in the third quarter worth about $26,000. Park Place Capital Corp acquired a new stake in IDEXX Laboratories during the 4th quarter valued at approximately $29,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $30,000. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories in the third quarter worth $31,000. Finally, Armstrong Advisory Group Inc. raised its holdings in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company's stock worth $34,000 after purchasing an additional 19 shares during the last quarter. Institutional investors own 87.84% of the company's stock.
About IDEXX Laboratories
(
Get Free Report)
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
